Veraflox (30 - 40 kg)

10 x 7 pc

Tablet

Active substance

Pradofloxacin : 120 mg

ATC code

QJ01MA97 Pradofloxacin

QJ01MA Fluoroquinolones

QJ01M Quinolone and quinoxaline antibacterials

QJ01 Antibacterials for systemic use

QJ Antiinfectives for systemic use

Species

Dogs, cats.

Indications

Dogs:

Treatment of:

• wound infections caused by strains of the Staphylococcus intermedius group (including S. pseudintermedius),

• superficial and deep pyoderma caused by strains of the Staphylococcus intermedius group (including S. pseudintermedius),

• acute urinary tract infections caused by strains of Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius) and

• as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by strains of anaerobic organisms, for example Porphyromonas spp. and Prevotella spp. (see section 3.5 Special precautions of use).

Cats:

Treatment of acute infections of the upper respiratory tract caused by strains of Staphylococcus intermedius group (including S. pseudintermedius), Pasteurella multocida and Escherichia coli.

Dose to be administered and administration route

Oral use.

The recommended dose is 3 mg/kg bodyweight of pradofloxacin once daily. To ensure a correct dosage, body weight should be determined as accurately as possible. Due to the available tablet sizes the resulting dose range is 3 to 4.5 mg/kg bodyweight according to the following tables.

When the dose requires a half tablet to be used the remaining portion should be given at the next administration.

Dogs:

Bodyweight (kg)	Strength and number of tablets
Bodyweight (kg)	15 mg	60 mg	120 mg
>3.4 – 5	1
>5 – 7.5	1½
>7.5 – 10	2
>10 – 15	3
>15 – 20		1
>20 – 30		1½
>30 – 40			1
>40 – 60			1½
>60 – 80			2

Cats:

Bodyweight (kg)	Strength and number of tablets
Bodyweight (kg)	15 mg
>3.4 – 5	1
>5 – 7.5	1½
>7.5 – 10	2

Duration of treatment

The duration of the treatment depends on the nature and severity of the infection and on the response to treatment. For most infections the following treatment courses will be sufficient:

Dogs:

Indication	Duration of treatment (days)
Skin infections:
Superficial pyoderma	14 – 21
Deep pyoderma	14 – 35
Wound infections	7
Acute infections of the urinary tract	7 – 21
Severe infections of the gingiva and periodontal tissues	7

The treatment should be re-considered if no improvement of the clinical conditions is observed within 3 days, or in cases of superficial pyoderma 7 days, and in cases of deep pyoderma 14 days, after starting the treatment.

Cats:

Indication	Duration of treatment (days)
Acute infections of the upper respiratory tract	5

The treatment should be re-considered if no improvement of the clinical condition is observed within 3 days after starting the treatment.

Adverse reactions

Dogs and cats:

Rare

(1 to 10 animals / 10,000 animals treated):

Digestive tract disorder (e.g. Vomiting)¹

¹ Mild and transient

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.